Future oncology最新文献_第7页

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing. 在缺乏MGMT启动子甲基化测试的情况下，对idh -野生型胶质母细胞瘤的RANO临床风险评分的实用适应性。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-08-04 DOI: 10.1080/14796694.2026.2713370

İmdat Eroğlu, Sıla Soylu Koçoğlu, Eron Merovci, Gözde Savaş, Fatih Gürler, Osman Sutcuoglu, Ugur Coskun, Aytug Uner, Murat Ucar, Burak Karaarslan, Ahmet Özet, Nuriye Özdemir, Ozan Yazıcı

{"title":"A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.","authors":"İmdat Eroğlu, Sıla Soylu Koçoğlu, Eron Merovci, Gözde Savaş, Fatih Gürler, Osman Sutcuoglu, Ugur Coskun, Aytug Uner, Murat Ucar, Burak Karaarslan, Ahmet Özet, Nuriye Özdemir, Ozan Yazıcı","doi":"10.1080/14796694.2026.2713370","DOIUrl":"10.1080/14796694.2026.2713370","url":null,"abstract":"Background: The novel RANO risk score provides prognostic stratification for patients with IDH-wildtype glioblastoma(GBM) and includes age, Karnofsky Performance Scale(KPS), RANO resection class(RRC), and MGMT promoter methylation(MGMTm). However, MGMTm testing is unavailable in many countries. We aimed to explore the prognostic performance of a RANO-adapted clinical score excluding MGMTm.Methods: We applied the same scoring system established by original RANO score, excluding MGMTm. Three risk classes were defined as numerical scores derived through tertiles. The primary endpoint was overall survival(OS), and the secondary exploratory endpoint was progression-free survival(PFS).Results: One-hundred twenty patients were included. Three risk classes were identified:low-risk(0-1 points,n:47, 39.2%), intermediate-risk(2-3 points,n:27, 22.5%), and high-risk(≥4 points,n:46, 38.3%). The median OS was 35.5 months(95% CI:21.1-49.9) for the low-risk group, 16 months(95% CI:9.9-22.1) for the intermediate-risk group, and 5 months(95% CI:3.6-6.3) for the high-risk group(p < 0.001). Similarly, the median PFS was 16.3 months(95% CI:12.3-20.3) for the low-risk group, 9.9 months(95% CI:7.2-12.6) for the intermediate-risk group, and 4.1 months(95% CI:3.5-4.7) for the high-risk group(p < 0.001).Conclusion: This simplified RANO-adapted score demonstrated promising prognostic stratification using basic clinical parameters. As a pragmatic adaptation study, external validation is required before clinical application, particularly in settings where MGMTm testing is unavailable.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2323-2333"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma. 一项评估适应性免疫疗法联合VEGFR-TKI治疗晚期肾细胞癌的可行性和临床疗效的II期研究。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-09-10 DOI: 10.1080/14796694.2026.2717069

Firas Hatoum, Brandon Dyer, Jazlyn Heiligh, Trey Poehlman, Jingsong Zhang, Gigi Jameel, Sarah Mizelle, Aditi Patel, Amy Schneider, Adnan Fazili, Jeffrey S Johnson, Justin W Miller, Gabriel Roman Souza, Nadine Mahmoud, Keerthi Gullapalli, Youngchul Kim, Philippe E Spiess, Robert Gatenby, Alexander R A Anderson, Jad Chahoud

{"title":"A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma.","authors":"Firas Hatoum, Brandon Dyer, Jazlyn Heiligh, Trey Poehlman, Jingsong Zhang, Gigi Jameel, Sarah Mizelle, Aditi Patel, Amy Schneider, Adnan Fazili, Jeffrey S Johnson, Justin W Miller, Gabriel Roman Souza, Nadine Mahmoud, Keerthi Gullapalli, Youngchul Kim, Philippe E Spiess, Robert Gatenby, Alexander R A Anderson, Jad Chahoud","doi":"10.1080/14796694.2026.2717069","DOIUrl":"10.1080/14796694.2026.2717069","url":null,"abstract":"Kidney cancer is one of the 10 most common cancers affecting both men and women in the United States, accounting for 4% to 5% of all cancers. Most recent estimates have shown that about 81,610 new cases of kidney cancer will be diagnosed in 2024, with renal cell carcinoma (RCC). The treatment landscape of metastatic or unresectable locally advanced clear cell renal cell carcinoma (ccRCC) has changed over the past years with the approval of multiple combination regimens using immune checkpoint inhibitors (ICI) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). However, this first‑line approach is associated with immense drug-related toxicity and financial burden. Recent research suggests that unlike traditional intermittent therapy, adaptive therapy modulates drug administration based on real-time tumor metrics to maintain a stable population of sensitive cells that suppress the growth of resistant clones. This phase II trial will assess the feasibility, patient acceptability, safety, and preliminary efficacy signals of a response-based multi-drug adaptive therapy approach with pembrolizumab-axitinib (pembro-axi) in patients with metastatic or unresectable locally advanced ccRCC.Clinical trial registration www.clinicaltrials.gov identifier is NCT06860386.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2467-2475"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study. Talquetamab用于复发/难治性多发性骨髓瘤患者：MonumenTAL-1研究的简明语言总结

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-08-30 DOI: 10.1080/14796694.2026.2709901

Ajai Chari, Cyrille Touzeau, Jesus G Berdeja, Albert Oriol, Niels Wcj van de Donk, Paula Rodríguez-Otero, Daniel Morillo, Carmen Martinez-Chamorro, María-Victoria Mateos, Luciano J Costa, Jo Caers, Leo Rasche, Amrita Krishnan, Jing Christine Ye, Lionel Karlin, Brea Lipe, Tara Masterton, Jaszianne Tolbert, Thomas Renaud, Colleen Kane, Christoph Heuck, Philippe Moreau

引用次数: 0

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors. 放射性碘难治性和非难治性DTC患者预后差异：生存率和独立危险因素的队列研究

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-08-10 DOI: 10.1080/14796694.2026.2715231

Menghua Xia, Weifu Lv, Wei Zhao, Liqin Bi, Xueran Guo, Mengxia Zhang, Liangping Shi

{"title":"Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.","authors":"Menghua Xia, Weifu Lv, Wei Zhao, Liqin Bi, Xueran Guo, Mengxia Zhang, Liangping Shi","doi":"10.1080/14796694.2026.2715231","DOIUrl":"10.1080/14796694.2026.2715231","url":null,"abstract":"Aims: Patients with distant metastases of differentiated thyroid cancer (DM-DTC) exhibit significant heterogeneity in clinical characteristics and prognosis. This study aimed to investigate prognostic variables affecting overall survival (OS) in radioiodine-refractory (RAIR) patients and to predict the radioiodine therapy (RAIT) response and stimulated thyroglobulin (sTg) levels in non-radioiodine-refractory (NRAIR) patients.Methods: A retrospective analysis was conducted on 146 patients of DM-DTC undergoing RAIT, categorizing them into an RAIR group (n = 56) and an NRAIR group (n = 90). Kaplan-Meier assessed survival, Cox regression identified RAIR prognostic factors, and logistic regression explored sTg-treatment response in NRAIR.Results: The median follow-up period was 71 months (IQR: 24-132 months).In RAIR, brain metastasis (HR = 5.49, 95% CI: 1.46-20.66, p = 0.012) and other-site metastases (HR = 4.11, 95% CI: 1.06-15.85, p = 0.004) were independent poor prognostic factors. In NRAIR, sTg ≤ 75 ng/mL predicted favorable response (sensitivity 84.8%, specificity 78.9%).Conclusions: RAIR status significantly impacts DM-DTC prognosis. Brain metastases or other-site metastases are independent prognostic factors in RAIR patients, highlighting the need for stratified treatment. In NRAIR patients, preliminary data suggest that sTg ≤ 75 ng/mL predicts a favorable treatment response.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2335-2346"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer. 皮下注射与静脉注射阿米伐他单加拉泽替尼治疗egfr改变的非小细胞肺癌的简单语言总结。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-08-24 DOI: 10.1080/14796694.2026.2709936

Natasha B Leighl, Antonio Passaro, Hiroaki Akamatsu, Alexander I Spira, Danny Nguyen, Angel Qin, Julia Schuchard, Mohamed Gamil, Mahadi Baig, Mariam Alexander

引用次数: 0

Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma. axicabtagene ciloleucel用于复发或难治性慢生长非霍奇金淋巴瘤患者的ZUMA-5研究的简明语言总结。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-09-16 DOI: 10.1080/14796694.2026.2719395

Sattva S Neelapu, Olga Nikolajeva, Caron A Jacobson

引用次数: 0

Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience. 派姆单抗一线治疗转移性非小细胞肺癌的实际有效性：十年的证据和经验

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-07-30 DOI: 10.1080/14796694.2026.2709201

Riddhi A Babel, Stephen V Liu, Tao Fan, Mayur M Amonkar, Vamsidhar Velcheti

{"title":"Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.","authors":"Riddhi A Babel, Stephen V Liu, Tao Fan, Mayur M Amonkar, Vamsidhar Velcheti","doi":"10.1080/14796694.2026.2709201","DOIUrl":"10.1080/14796694.2026.2709201","url":null,"abstract":"Non-small cell lung cancer (NSCLC) remains a global burden, particularly due to late‑stage diagnosis. Immune checkpoint inhibitors (ICIs) for mNSCLC, including first-line (1L) pembrolizumab regimens, significantly improved survival for these patients, establishing them as the current standard of care (SoC). Since the approvals of pembrolizumab, a large volume of real-world evidence (RWE) has been published across patient populations and with long-term follow-ups. This narrative review evaluates the available RWE on PubMed and Embase, assessing real-world clinical outcomes from 2016 to 2026 against pembrolizumab (KEYNOTE) clinical trials. Across geographies and practice settings, RWE for 1L pembrolizumab in mNSCLC is supportive of KEYNOTE findings, with survival outcomes comparable to the trials. Among heterogeneous populations, older age did not alter outcomes; however, cohorts with higher performance scores expectedly experienced poorer outcomes. Global treatment patterns highlighted pembrolizumab-containing regimens as the most administered ICI, affirming its role as SoC in 1L mNSCLC treatment. The volume of RWE studies, long-term follow-up data, and consistency in results observed across regions and diverse patient populations reinforce the use of pembrolizumab regimens as 1L SoC for patients with mNSCLC. Further analysis on the impact of heterogeneous subpopulations on the efficacy of pembrolizumab would be beneficial to support evidence-based decision-making.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2347-2366"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148619338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipid biomarkers of prostate cancer: insights from triglycerides and saturated fatty acid metabolism. 前列腺癌的脂质生物标志物：从甘油三酯和饱和脂肪酸代谢的见解。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-07-23 DOI: 10.1080/14796694.2026.2707002

Jia Wei He, Pei Zhen Li

{"title":"Lipid biomarkers of prostate cancer: insights from triglycerides and saturated fatty acid metabolism.","authors":"Jia Wei He, Pei Zhen Li","doi":"10.1080/14796694.2026.2707002","DOIUrl":"10.1080/14796694.2026.2707002","url":null,"abstract":"Background: Prostate cancer poses a substantial threat to men's health. Previous studies have hinted at potential links between dietary components like lipids and saturated fatty acids (SFAs) and prostate cancer, yet the precise relationships remain elusive.Methods: A multicenter case-control study was executed. A total of 120 pathologically confirmed prostate cancer patients and 60 age- and BMI-matched healthy male controls were enrolled. High performance liquid chromatography (HPLC) was employed to quantitatively analyze the levels of saturated, monounsaturated, and polyunsaturated fats in both prostate cancer tissues and adjacent tissues. Statistical analyses were conducted using SPSS version 23.0 software.Results: Triglycerides (OR = 4.23, 95% CI: 2.15-8.32, p < 0.001) and saturated fatty acid/fatty acid ratio (OR = 3.89, 95% CI: 1.98-7.64, p < 0.001) were significantly associated with prostate cancer risk. Both indicators were positively correlated with continuous Gleason score (triglyceride: β = 0.710, OR = 2.89, 95% CI: 1.96-4.26, p < 0.001; saturated fatty acid/fatty acid: β = 0.645, OR = 2.57, 95% CI: 1.78-3.71, p < 0.001), and were significantly elevated in prostate cancer tissues compared with adjacent non-cancerous tissues.Conclusion: This study confirms the importance of triglycerides and saturated fatty acid/fatty acid ratio in prostate cancer progression, which could be used for diagnosis and prognosis. Reducing their levels may help prevent prostate cancer.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2279-2286"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma. Belantamab mafodotin，一种bcma导向的多发性骨髓瘤抗体-药物偶联物。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-07-08 DOI: 10.1080/14796694.2026.2700028

Marina Samuel, Marcus S Flores, Jacob A Lowy, Michael F Rogers, Zachary M Avigan, Mohammad A Rattu, Joshua Richter

{"title":"Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma.","authors":"Marina Samuel, Marcus S Flores, Jacob A Lowy, Michael F Rogers, Zachary M Avigan, Mohammad A Rattu, Joshua Richter","doi":"10.1080/14796694.2026.2700028","DOIUrl":"10.1080/14796694.2026.2700028","url":null,"abstract":"Belantamab mafodotin-blmf (bela-maf) is a first-in-class antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA) for the treatment of multiple myeloma. Its unique structure allows it to induce plasma cell apoptosis through microtubule inhibition, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). While bela-maf failed to show efficacy as monotherapy for relapsed/refractory myeloma in its initial phase 3 trial, it subsequently showed significant improvement in progression-free survival in combination with either bortezomib/dexamethasone (BVd, DREAMM-7) or pomalidomide/dexamethasone (BPd, DREAMM-8) resulting in updated regulatory approval. Bela-maf is an \"off-the-shelf\" BCMA-directed therapy with decreased risk of severe infections compared to other T cell redirection strategies, but it results in high incidence of ocular toxicity including keratopathy, blurred vision, and dry eye due to target-independent uptake of the monomethyl auristatin F (MMAF) payload in the corneal epithelium. Bela-maf-induced ocular toxicity requires close ophthalmology monitoring and may be partially mitigated by reducing the dose or frequency of bela-maf, and further data are needed to optimize dosing strategies. Herein, we review the pharmacology, clinical efficacy, and unique safety precautions related to belantamab mafodotin, as well as highlight ongoing studies of its use in earlier lines of therapy and in combination with other anti-myeloma agents.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2131-2142"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PSMA-PET/mpMRI-guided focal dose-escalated stereotactic body radiotherapy for localized prostate cancer: study protocol for a prospective, randomized controlled trial. PSMA-PET/ mpmri引导的局灶剂量递增立体定向放疗治疗局限性前列腺癌：前瞻性随机对照试验的研究方案

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-08-18 DOI: 10.1080/14796694.2026.2714703

Wen-Sa Peng, Wei Zou, Shanwen Chen, Haowen Jiang, En-Min Wang, Zhi-Yong Qin, Hua-Guang Zhu, Xin Wang

{"title":"PSMA-PET/mpMRI-guided focal dose-escalated stereotactic body radiotherapy for localized prostate cancer: study protocol for a prospective, randomized controlled trial.","authors":"Wen-Sa Peng, Wei Zou, Shanwen Chen, Haowen Jiang, En-Min Wang, Zhi-Yong Qin, Hua-Guang Zhu, Xin Wang","doi":"10.1080/14796694.2026.2714703","DOIUrl":"10.1080/14796694.2026.2714703","url":null,"abstract":"Stereotactic body radiotherapy (SBRT) is effective for localized prostate cancer, yet many recurrences originate from the intraprostatic tumor mass (ITM). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) and multiparametric magnetic resonance imaging (mpMRI) enable precise ITM localization and support focal dose escalation. This trial assesses whether PSMA-PET/mpMRI-guided boosting during SBRT improves biochemical control without excess toxicity. This is a single-center, prospective, randomized (1:1), controlled, open-label clinical trial conducted at Huashan Hospital, Fudan University. A total of 128 men with newly diagnosed localized prostate adenocarcinoma will be enrolled and randomized to receive either (1) standard SBRT (39 Gy in 6 fractions) or (2) PSMA-PET/mpMRI-guided focal dose-escalated SBRT (up to 48 Gy in 6 fractions). All participants will receive androgen deprivation therapy (ADT) according to National Comprehensive Cancer Network (NCCN) risk group and clinical practice. The primary endpoint is biochemical progression-free survival (PSA-PFS), defined by the Phoenix criteria. Secondary endpoints include local progression-free survival (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), prostate cancer-specific survival (PCSS), toxicity (CTCAE v5.0), and patient-reported quality of life (EPIC-26 and SF-12). Survival outcomes will be analyzed using Kaplan-Meier estimates and compared via log-rank testing.Clinical trial registration:www.chictr.org.cnidentifier ChiCTR2500114310.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2457-2465"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0